Patents Examined by D Margaret M Seaman
  • Patent number: 10669291
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, Eric Easom, Yvonne Freund, Jacob J. Plattner, Jessica Sligar, Daitao Chen, Jennifer Freeman, Joe Perales
  • Patent number: 10662200
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: May 26, 2020
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Thuy-Anh Tran, Quyen-Quyen Do, Brett Ullman, Anthony C. Blackburn, Maiko Nagura
  • Patent number: 10662192
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: May 26, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Hadida-Ruah, Anna Hazlewood, Peter Grootenhuis, Fredrick Van Goor, Ashvani Singh, Jinglan Zhou, Jason McCartney
  • Patent number: 10660884
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: May 26, 2020
    Assignee: University of Rochester
    Inventors: Robert Boeckman, Brendan Boyce, Lifeng Xiao, Zhenqiang Yao, Frank H. Ebetino
  • Patent number: 10654866
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 19, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall
  • Patent number: 10654844
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 19, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Patent number: 10646494
    Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Ling Tong, Joseph A. Kozlowski, Craig A. Coburn, De-Yi Yang, Deyou Sha, Jae-Hun Kim, Michael Dwyer, Kartik M Keertikar, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang
  • Patent number: 10647699
    Abstract: The present invention relates to compounds of the general formula (I) in which Q, V, T, W, X, Y and A have the meanings given in the description—and to their use for controlling animal pests.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 12, 2020
    Assignee: Bayer CropScience Aktiengesellschaft
    Inventors: Johannes-Rudolf Jansen, Markus Heil, Reiner Fischer, David Wilcke, Matthieu Willot, Kerstin Ilg, Sascha Eilmus, Peter Lösel, Wolfram Andersch
  • Patent number: 10647693
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the manufacture of medicaments for treating of influenza.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 12, 2020
    Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Changhua Tang, Qingyun Ren, Junjun Yin, Kai Yi, Yingjun Zhang
  • Patent number: 10632122
    Abstract: The present disclosure is directed to compositions and methods for inhibiting either Toxoplasma gondii (T. gondii) calcium dependent protein kinases (TgCDPKs) or Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R1, and R3 are defined herein.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 28, 2020
    Assignee: University of Washington
    Inventors: Wilhelmus G. J. Hol, Eric T. Larson, Dustin James Maly, Wesley C. Van Voorhis, Ethan Merritt, Kayode K. Ojo
  • Patent number: 10633340
    Abstract: The present invention relates to a new route to bis-quaternary pyridinium oximes which can be utilized to restore activity of acetylcholinesterase inhibited by combination with organophosphates.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: April 28, 2020
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Shawn T. Blumberg, Antonio A Menchaca
  • Patent number: 10618920
    Abstract: Modified silica particles are provided. Aspects of the particles include an outer layer that is composed of organically-modified silica comprising a siloxane-linked hydrophilic group, such as a charged functional group or a polar neutral functional group. The modified silica particles can form the basis of a variety of chromatography support materials. Also provided are methods of preparing the subject particles. Aspects of the methods include contacting silica particles with water, an ionic fluoride and an organosilane reagent comprising a hydrophilic moiety to produce modified silica particles wherein the hydrophilic moiety of the organosilane reagent is incorporated into an outer layer of the silica particles. Chromatography supports and kits including the subject particles and methods of using the same are also provided.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 14, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Wu Chen, Yingyu Li, Ta-Chen Wei, Xiaoli Wang
  • Patent number: 10611750
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 7, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
  • Patent number: 10604480
    Abstract: The invention provides compounds of formula I and II and salts thereof, wherein R1, R2, Y, R3, and R4 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 31, 2020
    Assignees: Rutgers, The State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu
  • Patent number: 10597377
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: March 24, 2020
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jian Zhao, Shimiao Wang, Yunfei Zhu
  • Patent number: 10588894
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 17, 2020
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Patent number: 10588966
    Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 17, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Samir N. Khleif, Mikayel Mkrtichyan
  • Patent number: 10577339
    Abstract: A method for manufacturing furan-2,5-dicarboxylic acid (FDCA) by converting a furan-2,5-dicarboxylate salt (MFDC) into FDCA, including the steps of combining an aqueous solution of MFDC with a concentration of at least 5 wt. % with an inorganic acid (HY), to form a reaction mixture including solid FDCA in a concentration of 1-15 wt. % in a salt solution resulting from the cation of furan-2,5-dicarboxylate salt and the anion of the inorganic acid (MY solution), removing solid FDCA from the reaction mixture in a solid/liquid separation step, and providing part of the MY solution resulting from the solid/liquid separation step to the step of combining MFDC with HY. The step of providing part of MY salt solution resulting from the solid/liquid separation step to the step of combining MFDC with HY makes it possible to obtain a stable and economic process which results in an FDCA product with good quality and high yield.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: March 3, 2020
    Assignee: PURAC BIOCHEM BV
    Inventors: Jan Van Krieken, Andre Banier De Haan
  • Patent number: 10568874
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: February 25, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Christopher Lange, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 10562903
    Abstract: The present invention relates to a compound of formula wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, —CH2—C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n=2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 18, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Hasane Ratni, Karlheinz Baumann, Guido Galley, Georg Jaeschke, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Rosa Maria Rodriguez-Sarmiento